<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id>
<journal-id journal-id-type="publisher-id">ECAM</journal-id>
<journal-title-group>
<journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title>
</journal-title-group>
<issn pub-type="ppub">1741-427X</issn>
<issn pub-type="epub">1741-4288</issn>
<publisher>
<publisher-name>Hindawi</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31467573</article-id>
<article-id pub-id-type="pmc">6699265</article-id>
<article-id pub-id-type="doi">10.1155/2019/2745453</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Attenuation Effects of Alpha-Pinene Inhalation on Mice with Dizocilpine-Induced Psychiatric-Like Behaviour</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-0360-5761</contrib-id>
<name>
<surname>Ueno</surname>
<given-names>Hiroshi</given-names>
</name>
<email>dhe422007@s.okayama-u.ac.jp</email>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shimada</surname>
<given-names>Atsumi</given-names>
</name>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Suemitsu</surname>
<given-names>Shunsuke</given-names>
</name>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murakami</surname>
<given-names>Shinji</given-names>
</name>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kitamura</surname>
<given-names>Naoya</given-names>
</name>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wani</surname>
<given-names>Kenta</given-names>
</name>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>Yosuke</given-names>
</name>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Okamoto</surname>
<given-names>Motoi</given-names>
</name>
<xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ishihara</surname>
<given-names>Takeshi</given-names>
</name>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
</contrib-group>
<aff id="I1">
<sup>1</sup>Department of Medical Technology, Kawasaki University of Medical Welfare, Okayama, 701-0193, Japan</aff>
<aff id="I2">
<sup>2</sup>Division of Food and Nutrition, Nakamura Gakuen University Junior College, Fukuoka, 814-0198, Japan</aff>
<aff id="I3">
<sup>3</sup>Department of Psychiatry, Kawasaki Medical School, Kurashiki, 701-0192, Japan</aff>
<aff id="I4">
<sup>4</sup>Department of Neuropsychiatry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, 700-8558, Japan</aff>
<aff id="I5">
<sup>5</sup>Department of Medical Technology, Graduate School of Health Sciences, Okayama University, Okayama, 700-8558, Japan</aff>
<author-notes>
<fn fn-type="other">
<p>Academic Editor: Jenny M. Wilkinson</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>7</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>2019</volume>
<elocation-id>2745453</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Hiroshi Ueno et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>
<italic>α</italic>-Pinene, an organic terpene compound found in coniferous trees, is used as a safe food additive and is contained in many essential oils. Moreover, some studies have shown that <italic>α</italic>-pinene suppresses neuronal activity. In this study, we investigated whether inhalation of <italic>α</italic>-pinene suppresses dizocilpine (MK-801-) induced schizophrenia-like behavioural abnormalities in mice. Mice inhaled <italic>α</italic>-pinene 1 h before the first MK-801 injection. Thirty minutes after MK-801 injection, the open field, spontaneous locomotor activity, elevated plus maze, Y-maze, tail suspension, hot plate, and grip strength tests were conducted as behavioural experiments. Inhalation of <italic>α</italic>-pinene suppressed the activity of mice in the spontaneous locomotor activity test and although it did not suppress the MK-801-induced increased locomotor activity in the open field test, it remarkably decreased the time that the mice remained in the central area. Inhalation of <italic>α</italic>-pinene suppressed the MK-801-induced increased total distance travelled in the Y-maze test, whereas it did not alter the MK-801-induced reduced threshold of antinociception in the hot plate test. In the tail suspension and grip strength tests, there was no effect on mouse behaviour by administration of MK-801 and inhalation of <italic>α</italic>-pinene. These results suggest that <italic>α</italic>-pinene acts to reduce MK-801-induced behavioural abnormalities resembling those seen in neuropsychiatric disorders. Therefore, both medicinal plants and essential oils containing <italic>α</italic>-pinene may have potential for therapeutic treatment of schizophrenia.</p>
</abstract>
<funding-group>
<award-group>
<funding-source>Towa Foundation for Food Science &amp; Research</funding-source>
</award-group>
<award-group>
<funding-source>Kobayashi Magobe Memorial Medical Foundation</funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
<body>
<sec id="sec1">
<title>1. Introduction</title>
<p>Schizophrenia is a chronic and degenerative disease, with an overall lifetime risk of 1%. Despite its high prevalence, the pathogenesis of schizophrenia is not clear [<xref ref-type="bibr" rid="B58">1</xref>, <xref ref-type="bibr" rid="B7">2</xref>]. Current antipsychotics are generally successful in treating positive symptoms (e.g., hallucinations and delusions) but have limited effect on the reduction of negative and cognitive symptoms and have side effects [<xref ref-type="bibr" rid="B36">3</xref>–<xref ref-type="bibr" rid="B67">6</xref>]. Therefore, there is a need for new therapeutic agents with fewer side effects. The side effects accompanying the use of synthetic drugs, together with their acquisition cost and supply shortage, have recently increased people's interest in using medicinal plants. Aromatherapy, an alternative type of medicine which uses medicinal plants, is widely used for the management of chronic pain, depression, anxiety, insomnia, and stress-related disorders [<xref ref-type="bibr" rid="B43">7</xref>, <xref ref-type="bibr" rid="B85">8</xref>]. However, the scientific basis underlying the mechanism of action of many medicinal plants and essential oils remains unclear [<xref ref-type="bibr" rid="B85">8</xref>, <xref ref-type="bibr" rid="B41">9</xref>]. Therefore, the need to clarify the scientific mechanism of medicinal plants considered to have a physiological effect is rapidly becoming more urgent [<xref ref-type="bibr" rid="B19">10</xref>]. Additionally, these medicinal plants are also an important source of new chemicals with potential therapeutic effects.</p>
<p>
<italic>α</italic>-Pinene is an organic terpene compound, which is contained in the oil of coniferous trees, and is the major monoterpene in pine trees [<xref ref-type="bibr" rid="B73">11</xref>]. <italic>α</italic>-Pinene is widely used as a food-flavouring ingredient [<xref ref-type="bibr" rid="B61">12</xref>, <xref ref-type="bibr" rid="B65">13</xref>] and has been approved as a safe food additive by the U.S. Food and Drug Administration [<xref ref-type="bibr" rid="B76">14</xref>]. In addition, <italic>α</italic>-pinene is also contained in essential oils such as in rosemary (<italic>Rosmarinus officinalis</italic>) oil,<italic> Eucalyptus</italic> oil, camphor,<italic> Bupleurum fruiticescens</italic>,<italic> Psidium</italic>, and<italic> Opuntia humifusa</italic>. Indeed, <italic>α</italic>-pinene is considered to have a physiological effect on humans [<xref ref-type="bibr" rid="B22">15</xref>, <xref ref-type="bibr" rid="B23">16</xref>], and essential oils containing <italic>α</italic>-pinene have been used to treat several diseases [<xref ref-type="bibr" rid="B48">17</xref>]. However, in humans, odours may lead to behavioural and cognitive changes, so careful interpretation is necessary. Inhalation of essential oils transfers signals from the olfactory system to the brain, and the brain regulates anxiety, depression, and mood disorders by secreting neurotransmitters such as serotonin and dopamine [<xref ref-type="bibr" rid="B43">7</xref>]. Therefore, various plant-derived essential oils have traditionally been used to treat psychiatric disorders such as depression, anxiety neurosis, attention-deficit hyperactivity disorder, and bipolar disorder. In addition, it has been reported that <italic>α</italic>-pinene also has anti-inflammatory [<xref ref-type="bibr" rid="B45">18</xref>, <xref ref-type="bibr" rid="B86">19</xref>], antidepressant [<xref ref-type="bibr" rid="B1">20</xref>], anticonvulsant [<xref ref-type="bibr" rid="B15">21</xref>], antioxidant [<xref ref-type="bibr" rid="B74">22</xref>], antitumoral [<xref ref-type="bibr" rid="B20">23</xref>], and antinociceptive effects [<xref ref-type="bibr" rid="B31">24</xref>]. In recent years, it has been reported that inhalation of <italic>α</italic>-pinene has anxiolytic effects on mice during the elevated plus maze test [<xref ref-type="bibr" rid="B69">25</xref>]. Inhalation of <italic>α</italic>-pinene also leads to the accumulation of <italic>α</italic>-pinene in the brain. Furthermore, it has been shown that inhalation of <italic>α</italic>-pinene significantly increases rapid eye movement in rats during sleep [<xref ref-type="bibr" rid="B82">26</xref>]. Although <italic>α</italic>-pinene reportedly acts on rodents' nerves by inhalation, it has not been investigated how <italic>α</italic>-pinene affects psychiatric-like behavioural abnormalities. Considering that <italic>α</italic>-pinene acts on the nervous system, <italic>α</italic>-pinene may be a potential therapeutic agent for psychoneurotic diseases including schizophrenia.</p>
<p>N-methyl-D-aspartate (NMDA) receptor antagonists such as dizocilpine (MK-801) are widely used for animal models of schizophrenia [<xref ref-type="bibr" rid="B54">27</xref>–<xref ref-type="bibr" rid="B39">30</xref>]. Administration of MK-801 alters the glutamatergic system in animal models and causes positive symptoms, negative symptoms, and cognitive impairment, similar to those seen in schizophrenia [<xref ref-type="bibr" rid="B4">31</xref>–<xref ref-type="bibr" rid="B18">35</xref>]. Many studies have reported the involvement of glutamatergic neurotransmission dysfunction via NMDA receptors in the pathophysiology of schizophrenia [<xref ref-type="bibr" rid="B33">36</xref>–<xref ref-type="bibr" rid="B42">40</xref>]. It is well established that the NMDA receptor plays an important role in the pathogenesis and pharmacological treatment of schizophrenia [<xref ref-type="bibr" rid="B26">33</xref>–<xref ref-type="bibr" rid="B18">35</xref>, <xref ref-type="bibr" rid="B34">41</xref>]. Thus, when a novel compound relieves MK-801-induced behavioural abnormalities, a range of tests can be widely used to evaluate its preclinical utility as a potential antipsychotic [<xref ref-type="bibr" rid="B21">42</xref>–<xref ref-type="bibr" rid="B59">44</xref>].</p>
<p>This study aimed to evaluate whether inhalation of <italic>α</italic>-pinene suppresses schizophrenia-like behaviour abnormalities induced by MK-801. We investigated whether MK-801-induced abnormal behaviours would be suppressed by preexposure to <italic>α</italic>-pinene through a series of behavioural experiments.</p>
</sec>
<sec id="sec2">
<title>2. Experimental Procedures</title>
<sec id="sec2.1">
<title>2.1. Animals</title>
<p>We used 15-week-old male mice (C57BL/6) for the experiments. We purchased the animals from Charles River Laboratories (Kanagawa, Japan) and housed them in cages with food and water provided<italic> ad libitum</italic> under a 12 h light/dark cycle at 23–26°C. We made every effort to minimize the number of animals used and their suffering. These experiments complied with the U.S. National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23, revised in 1996) and were approved by the Committee for Animal Experiments at Kawasaki Medical School Advanced Research Center.</p>
</sec>
<sec id="sec2.2">
<title>2.2. Drug Administration</title>
<p>(+)-MK-801 (dizocilpine hydrogen maleate; 130-17381, FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was diluted in saline at concentrations of 0.1 mg/mL and administered intraperitoneally (i.p.) in a volume of 0.2 mg/kg. This dose was selected on the basis of previous studies showing a schizophrenia-related deficient effect of MK-801 at 0.2 mg/kg in mice [<xref ref-type="bibr" rid="B57">45</xref>–<xref ref-type="bibr" rid="B11">47</xref>].</p>
</sec>
<sec id="sec2.3">
<title>2.3. Inhalation of <italic>α</italic>-Pinene</title>
<p>
<italic>α</italic>-Pinene was acquired from FUJIFILM Wako Pure Chemical Corporation (169-21242). Additionally, saline was used as a control. The inhalation apparatus was the same as that used in a previous study [<xref ref-type="bibr" rid="B77">48</xref>]. Inhalation of the odour was carried out in a sealed container. A piece of absorbent cotton (4 × 4 cm) impregnated with 2 mL of <italic>α</italic>-pinene was placed in a stainless-steel container (60 × 60 × 35 mm) capped by a lid with holes. The mice were unable to lick or touch the cotton. The stainless-steel container was placed in a new breeding cage (235 × 325 × 170 mm) surrounded by two larger cages (292 × 440 × 200 mm). Approximately 20 min after the cotton placement, the mice were placed in the internal cage for 30 min. Control group mice were placed in the same container without the <italic>α</italic>-pinene. After 30 min, the mice received either a dose of MK-801 or saline. The test was started 30 min after MK-801 treatment.</p>
</sec>
<sec id="sec2.4">
<title>2.4. Behavioural Tests</title>
<p>All behavioural experiments were performed during the light phase (9:00–16:00). We tested mice in a random order. After testing, the apparatus was cleaned with 70% ethanol and 80 ppm super hypochlorous water to prevent any bias due to olfactory cues [<xref ref-type="bibr" rid="B38">49</xref>]. Animals were randomly selected and divided, according to a table of random numbers, into four groups: a control (inhaled saline, administered saline), MK-801 group (inhaled saline, administered MK-801), MK-801 + <italic>α</italic>-pinene group (inhaled <italic>α</italic>-pinene, administered MK-801), and <italic>α</italic>-pinene group ((inhaled <italic>α</italic>-pinene, administered saline). Each animal was subjected to the open field test only once (n = 8 animals per group). Next, the animals were randomly divided into three groups: a control group, MK-801 group, and MK-801 + <italic>α</italic>-pinene group. Each animal was subjected to the locomotor activity test, elevated plus maze test, Y-maze test, hot plate test, neurological screening, and tail suspension test only once (n = 10 animals per group).</p>
</sec>
<sec id="sec2.5">
<title>2.5. Locomotor Activity Test</title>
<p>To assess whether exposure to <italic>α</italic>-pinene induced motor impairment or not, we examined locomotor activity under odour exposure. For measurements of locomotor activity, the mice were acclimated to the single housing environment (235 mm × 325 mm × 170 mm) for 3 h. Locomotor activity data were measured using a photobeam activity system (ACTIMO-100; BRC Co., Nagoya, Aichi, Japan). Sensors were located every 2 cm along the floor of the enclosure. Activity counts were expressed as the number of ambulations recorded at 10-min intervals. Mice were placed into photobeam activity arenas for 60 min before those in the MK-801 or saline groups were administered an injection [<xref ref-type="bibr" rid="B66">50</xref>]. Locomotion was measured for 3 h. “Control” group was treated with dH<sub>2</sub>O (inhalation) during the test period. “MK-801” group was treated with MK-801 (i.p.) and dH<sub>2</sub>O (inhalation) during the test period. “MK-801 + <italic>α</italic>-pinene” group was treated with MK-801 (i.p.) and <italic>α</italic>-pinene (inhalation) during the test period.</p>
</sec>
<sec id="sec2.6">
<title>2.6. Open Field Test</title>
<p>In the open field test, each mouse was placed at the centre of the apparatus, consisting of a square area surrounded by high walls (40 × 40 × 40 cm). The total distance travelled (m) and the time spent in the central area (s) were recorded [<xref ref-type="bibr" rid="B46">51</xref>]. The central area was defined as the 20 × 20-cm area located at the centre of the field. The test chamber was illuminated at 100 lux. Data were collected over a 30-min period. Data analysis was performed automatically using video tracking software (ANY-MAZE, Stoelting Co., Wood Dale, IL, USA).</p>
</sec>
<sec id="sec2.7">
<title>2.7. Elevated Plus Maze Test</title>
<p>The apparatus consisted of two open arms (8 × 25 cm) and two closed arms of the same size with 30 cm-high transparent walls, similar to previous studies [<xref ref-type="bibr" rid="B3">52</xref>, <xref ref-type="bibr" rid="B55">53</xref>]. The arms were made of white plastic plates and elevated to a height of 40 cm above the floor. Arms of the same type were located opposite each other. Each mouse was placed at the central square of the maze, facing one of the closed arms, and was allowed to move freely between the two arms for 10 min. The number of arm entries, distance travelled (m), and time (s) spent in the open arms were video recorded and analysed using the ANY-MAZE software.</p>
</sec>
<sec id="sec2.8">
<title>2.8. Y-Maze Test</title>
<p>Spatial working memory was measured using a Y-maze apparatus (arm length: 40 cm, arm bottom width: 3 cm, arm upper width: 10 cm, wall height: 12 cm). The protocol was similar to that used in a previous study [<xref ref-type="bibr" rid="B80">54</xref>]. Mice were placed at the centre of the Y-maze field. Visual cues were placed around the maze in the testing room and were constant throughout the testing sessions. Mice were examined with no prior learning. The number of entries and alterations was recorded and analysed automatically using the ANY-MAZE software. Data were collected for 10 min.</p>
</sec>
<sec id="sec2.9">
<title>2.9. Hot Plate Test</title>
<p>The hot plate test was used to evaluate the nociception or sensitivity to a painful stimulus [<xref ref-type="bibr" rid="B78">55</xref>]. It consisted of an electrically heated surface and an open Plexiglass box (20 × 20 × 30 cm) to contain the animals. Mice were placed on a hot plate at 55.0 ± 0.3°C, and the latency to the first hind-paw response was recorded. The hind-paw responses counted foot shakes or paw licks. A latency period of 30 s was defined as complete analgesia and used as the cut-off time to prevent tissue injuries.</p>
</sec>
<sec id="sec2.10">
<title>2.10. Neurological Screening</title>
<p>Neuromuscular strength was examined using the grip strength test according to a previous study [<xref ref-type="bibr" rid="B52">56</xref>]. A grip strength metre was used to assess forelimb grip strength. Mice were lifted and held by the tail such that their forepaws could grasp a wire grid; they were then pulled backward gently until they released the grid. The peak force applied by the forelimbs was recorded in Newtons (cN).</p>
</sec>
<sec id="sec2.11">
<title>2.11. Tail Suspension Test</title>
<p>Each mouse was suspended by the tail at 60 cm above the floor, in a white plastic chamber, using adhesive tape placed &lt;1 cm from the tip of the tail. Mouse behaviour was recorded for 6 min. Images were captured via a video camera, and immobility time was measured [<xref ref-type="bibr" rid="B46">51</xref>]. In this test, the ‘immobile period' was defined as the period when the animals stopped struggling for ≥ 1 s. Data acquisition and analysis were performed automatically using the ANY-MAZE software.</p>
</sec>
<sec id="sec2.12">
<title>2.12. Statistical Analyses of Behavioural Test Results</title>
<p>Data were analysed using one-way analysis of variance (ANOVA) followed by Tukey's test, two-way repeated measures ANOVA followed by Fisher's LSD test, Student's t-test, or paired t-test. A p-value of &lt; 0.05 was regarded as statistically significant. Data are presented as box plots.</p>
</sec>
</sec>
<sec id="sec3">
<title>3. Results</title>
<sec id="sec3.1">
<title>3.1. Effect of <italic>α</italic>-Pinene on MK-801-Induced Abnormal Behaviour in the Locomotor Activity Test</title>
<p>First, we tested whether <italic>α</italic>-pinene affects locomotor activity. Mice were pretreated with <italic>α</italic>-pinene before administration of MK-801. Pretreatment with <italic>α</italic>-pinene reduced basal activity (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>,<italic> F</italic><sub>17,459</sub> = 10.07, p &lt; 0.001; control vs. MK-801, p = 0.001; control vs. MK-801 + <italic>α</italic>-pinene, p &lt; 0.001, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 1.0, B,<italic> F</italic><sub>2,29</sub> = 7.348, p = 0.003; control vs. MK-801, p = 0.164; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.143, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.002). MK-801, an NMDA receptor antagonist, increases locomotor activity [<xref ref-type="bibr" rid="B12">57</xref>]. As shown in <xref ref-type="fig" rid="fig1">Figure 1(a)</xref>, the injection with MK-801 resulted in a robust increase in locomotor activity, which lasted for a further 120 min (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>). While the <italic>α</italic>-pinene pretreatment had a clear effect on basal activity, there was no effect on the MK-801-induced locomotor activity (Figures <xref ref-type="fig" rid="fig1">1(a)</xref> and <xref ref-type="fig" rid="fig1">1(c)</xref>,<italic> F</italic><sub>2,29</sub> = 15.134, p &lt; 0.001; control vs. MK-801, p = 0.001; control vs. MK-801 + <italic>α</italic>-pinene, p &lt; 0.001, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.654).</p>
</sec>
<sec id="sec3.2">
<title>3.2. Effect of <italic>α</italic>-Pinene on MK-801-Induced Abnormal Behaviour in the Open Field Test</title>
<p>In the open field test, we observed no significant difference in the total distance travelled between mice exposed to only <italic>α</italic>-pinene and control mice (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>,<italic> F</italic><sub>15,140</sub> = 2.275, p = 0.007; control vs. MK-801, p &lt; 0.001; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.008, control vs. <italic>α</italic>-pinene, p = 1.0, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 1.0, MK-801 vs. <italic>α</italic>-pinene, p &lt; 0.001, MK-801 + <italic>α</italic>-pinene vs. <italic>α</italic>-pinene, p = 0.007, <xref ref-type="fig" rid="fig2">Figure 2(c)</xref>,<italic> F</italic><sub>3,31</sub> = 5.762, p = 0.003; control vs. MK-801, p = 0.012; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.026, control vs. <italic>α</italic>-pinene, p = 0.952, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.99, MK-801 vs. <italic>α</italic>-pinene, p = 0.043, MK-801 + <italic>α</italic>-pinene vs. <italic>α</italic>-pinene, p = 0.083). No differences were observed in the time spent in the central area between mice exposed to only <italic>α</italic>-pinene and control mice (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>,<italic> F</italic><sub>15,140</sub> = 1.133, p = 0.333; control vs. MK-801, p = 0.002; control vs. MK-801 + <italic>α</italic>-pinene, p = 1.0, control vs. <italic>α</italic>-pinene, p = 1.0, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.013, MK-801 vs. <italic>α</italic>-pinene, p = 0.006, MK-801 + <italic>α</italic>-pinene vs. <italic>α</italic>-pinene, p = 1.0, <xref ref-type="fig" rid="fig2">Figure 2(d)</xref>,<italic> F</italic><sub>3,31</sub> = 7.186, p = 0.001; control vs. MK-801, p = 0.002; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.864, control vs. <italic>α</italic>-pinene, p = 0.966, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.011, MK-801 vs. <italic>α</italic>-pinene, p = 0.005, MK-801 + <italic>α</italic>-pinene vs. <italic>α</italic>-pinene, p = 0.989).</p>
<p>Administration of MK-801 markedly increased locomotor activity in mice (Figures <xref ref-type="fig" rid="fig2">2(a)</xref> and <xref ref-type="fig" rid="fig2">2(c)</xref>). Similarly, administration of MK-801 markedly increased locomotor activity in mice preexposed to <italic>α</italic>-pinene (Figures <xref ref-type="fig" rid="fig2">2(a)</xref> and <xref ref-type="fig" rid="fig2">2(c)</xref>). We observed no significant difference in the MK-801-induced hyperlocomotion between mice preexposed to <italic>α</italic>-pinene and those exposed to saline.</p>
<p>The time spent in the central area was significantly higher in mice administered MK-801 than in control mice (Figures <xref ref-type="fig" rid="fig2">2(b)</xref> and <xref ref-type="fig" rid="fig2">2(d)</xref>). Pretreatment with <italic>α</italic>-pinene significantly attenuated the MK-801-induced longer time spent in the central area (Figures <xref ref-type="fig" rid="fig2">2(b)</xref> and <xref ref-type="fig" rid="fig2">2(d)</xref>).</p>
</sec>
<sec id="sec3.3">
<title>3.3. Effect of <italic>α</italic>-Pinene on MK-801-Induced Abnormal Behaviour in the Elevated Plus Maze Test</title>
<p>In the elevated plus maze test, we evaluated anxiety-like behaviour in mice administered MK-801 after preexposure to <italic>α</italic>-pinene. Administration of MK-801 markedly increased the total distance travelled in mice preexposed to saline or <italic>α</italic>-pinene (<xref ref-type="fig" rid="fig3">Figure 3(a)</xref>,<italic> F</italic><sub>2,28</sub> = 14.157, p &lt; 0.001; control vs. MK-801, p &lt; 0.001; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.007, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.18).</p>
<p>Mice administered MK-801 had a significantly higher number of entries to open arms than did the control mice (<xref ref-type="fig" rid="fig3">Figure 3(b)</xref>,<italic> F</italic><sub>2,28</sub> = 8.342, p = 0.002; control vs. MK-801, p = 0.003; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.007, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.942). Similarly, mice administered MK-801 spent markedly increased time in the open arms than did the control mice (<xref ref-type="fig" rid="fig3">Figure 3(c)</xref>,<italic> F</italic><sub>2,28</sub> = 9.183, p = 0.001; control vs. MK-801, p = 0.001; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.039, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.269).</p>
<p>No differences were observed in the total distance travelled, the number of total entries into open arms, and the time spent in open arms between mice administered MK-801 exposed to <italic>α</italic>-pinene or exposed to saline.</p>
</sec>
<sec id="sec3.4">
<title>3.4. Effect of <italic>α</italic>-Pinene on MK-801-Induced Abnormal Behaviour in the Y-Maze Test</title>
<p>We examined the effect of <italic>α</italic>-pinene on the short-term spatial working memory of mice administered MK-801 by monitoring spontaneous alteration behaviour in the Y-maze test. Administration of MK-801 markedly increased locomotor activity in mice (<xref ref-type="fig" rid="fig4">Figure 4(a)</xref>,<italic> F</italic><sub>2,28</sub> = 13.284, p &lt; 0.001; control vs. MK-801, p &lt; 0.001; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.191, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.004). Similarly, administration of MK-801 markedly increased the number of arm entries (<xref ref-type="fig" rid="fig4">Figure 4(b)</xref>,<italic> F</italic><sub>2,28</sub> = 17.62, p &lt; 0.001; control vs. MK-801, p &lt; 0.001; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.435, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p &lt; 0.001). There were no significant differences between control mice and mice administered MK-801 preexposed to <italic>α</italic>-pinene in the total distance travelled (<xref ref-type="fig" rid="fig4">Figure 4(a)</xref>) and the number of arm entries (<xref ref-type="fig" rid="fig4">Figure 4(b)</xref>). No differences were observed in the alteration percentage among the three groups (<xref ref-type="fig" rid="fig4">Figure 4(c)</xref>,<italic> F</italic><sub>2,28</sub> = 1.086, p = 0.356; control vs. MK-801, p = 0.326; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.683, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.73).</p>
</sec>
<sec id="sec3.5">
<title>3.5. Effect of <italic>α</italic>-Pinene on MK-801-Induced Abnormal Behaviour in the Hot Plate Test and Neuromuscular Strength Test</title>
<p>We examined the effect of <italic>α</italic>-pinene on sensitivity to a painful stimulus in the hot plate test. Administration of MK-801 markedly decreased latency for the mice to lick their front paw (<xref ref-type="fig" rid="fig5">Figure 5(a)</xref>,<italic> F</italic><sub>2,28</sub> = 21.681, p &lt; 0.001; control vs. MK-801, p &lt; 0.001; control vs. MK-801 + <italic>α</italic>-pinene, p &lt; 0.001, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.4569). All mice administered MK-801 appeared to have a significantly higher pain threshold than mice administered saline (<xref ref-type="fig" rid="fig5">Figure 5(a)</xref>). No differences were observed in latency between mice administered MK-801 preexposed to <italic>α</italic>-pinene and exposed to saline.</p>
<p>We compared the neuromuscular strength of mice preexposed to <italic>α</italic>-pinene and mice preexposed to saline administered MK-801. No differences were observed in grip strength among the three groups (<xref ref-type="fig" rid="fig5">Figure 5(b)</xref>,<italic> F</italic><sub>2,28</sub> = 1.622, p = 0.217; control vs. MK-801, p = 0.99; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.306, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.264).</p>
</sec>
<sec id="sec3.6">
<title>3.6. Effect of <italic>α</italic>-Pinene on MK-801-Induced Abnormal Behaviour in the Tail Suspension Test</title>
<p>We evaluated depressive-like behaviour in mice administered MK-801 after <italic>α</italic>-pinene inhalation. In the tail suspension test, we found no significant differences among the three groups (<xref ref-type="fig" rid="fig6">Figure 6(a)</xref>,<italic> F</italic><sub>2,28</sub> = 1.247, p = 0.304; control vs. MK-801, p = 0.284; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.576, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 0.838, B,<italic> F</italic><sub>2,28</sub> = 0.109, p = 0.897; control vs. MK-801, p = 0.398; control vs. MK-801 + <italic>α</italic>-pinene, p = 0.965, MK-801 vs. MK-801 + <italic>α</italic>-pinene, p = 1.0).</p>
</sec>
</sec>
<sec id="sec4">
<title>4. Discussion</title>
<p>In this study, we evaluated the ability of <italic>α</italic>-pinene, which is widely used for food flavouring, to suppress and treat abnormal behaviour in a MK-801-induced mental disease mouse model. We investigated whether abnormal behaviour induced by administration of MK-801 would be alleviated by inhalation of <italic>α</italic>-pinene by conducting the open field, Y-maze, tail suspension, and elevated plus maze tests. The main finding of this study was that inhalation of <italic>α</italic>-pinene significantly reduced the abnormal behaviour of mice (hyperactivity and decreased anxiety-like behaviours) induced by MK-801 administration. To our knowledge, this is the first report that inhalation of <italic>α</italic>-pinene can reduce behavioural changes induced by NMDA receptor antagonists. Therefore, our findings indicate that <italic>α</italic>-pinene has potential antipsychotic activity in animal models of schizophrenia.</p>
<p>Open field testing is a useful behavioural experiment that is widely used to evaluate animal spontaneous activity and anxiety-like behaviour [<xref ref-type="bibr" rid="B5">58</xref>, <xref ref-type="bibr" rid="B64">59</xref>]. It has been reported that spontaneous activity decreases by intraperitoneal administration of <italic>α</italic>-pinene to rats [<xref ref-type="bibr" rid="B84">60</xref>]. However, in the open field test, the amount of activity did not decrease in mice that were preexposed to <italic>α</italic>-pinene. However, during inhalation of <italic>α</italic>-pinene, a decrease in activity was confirmed in the locomotor activity test. Differences in these results are presumed to be due to differences in animal species, methods of administering <italic>α</italic>-pinene, concentration of administration, and inhalation time.</p>
<p>Similar behaviour was observed in this study, as it has been shown that administration of MK-801 in rodents increases activity in open field tests [<xref ref-type="bibr" rid="B17">61</xref>, <xref ref-type="bibr" rid="B63">62</xref>]. However, <italic>α</italic>-pinene did not have the effect of suppressing the increase in activity in the open field test and locomotor activity test. In contrast, inhalation of <italic>α</italic>-pinene suppressed the MK-801-induced decrease in anxiety-like behaviour. This may be because the cognitive function of mice was not reduced by the sedative effect of <italic>α</italic>-pinene [<xref ref-type="bibr" rid="B40">63</xref>]. Although further research is needed to elucidate the clear mechanism, this experimental result strongly suggests that <italic>α</italic>-pinene reduces abnormal behaviours induced by MK-801.</p>
<p>As described in the introduction section, several studies have already reported the effects of inhalation of <italic>α</italic>-pinene [<xref ref-type="bibr" rid="B43">7</xref>, <xref ref-type="bibr" rid="B48">17</xref>, <xref ref-type="bibr" rid="B1">20</xref>, <xref ref-type="bibr" rid="B69">25</xref>]. It has not been reported that inhalation of <italic>α</italic>-pinene suppresses psychiatric disorder-like behaviour. The purpose of this study is to clarify whether MK-801 induced behavioural abnormalities can be suppressed by inhalation of <italic>α</italic>-pinene. Therefore, the group who only inhaled <italic>α</italic>-pinene was excluded.</p>
<p>MK-801 administration is considered to cause an increase in activity level and a decrease in anxiety-like behaviour in the elevated plus maze [<xref ref-type="bibr" rid="B71">64</xref>, <xref ref-type="bibr" rid="B6">65</xref>]. Moreover, in this study, administration of MK-801 caused an increase in activity level and a decrease in anxiety-like behaviour in mice. <italic>α</italic>-Pinene did not alleviate behavioural abnormalities in mice induced by administration of MK-801 in this experiment.</p>
<p>The spontaneous alteration score in the Y-maze test is an index of working memory and spatial cognitive function [<xref ref-type="bibr" rid="B13">66</xref>, <xref ref-type="bibr" rid="B72">67</xref>]. Administration of MK-801 reportedly reduces spontaneous alteration scores in rodents [<xref ref-type="bibr" rid="B50">68</xref>, <xref ref-type="bibr" rid="B56">69</xref>]. In this study, the spontaneous alteration scores of MK-801 treated mice tended to be lower than those of control mice, but no significant difference was found among the three groups. In fact, it has been reported that spontaneous alteration does not decrease significantly by MK-801 administration [<xref ref-type="bibr" rid="B29">70</xref>]. Differences in these results are presumed to be due to differences in mouse strain or MK-801 administration concentration. However, in this Y-maze test, MK-801 caused an increase in activity level in mice, while <italic>α</italic>-pinene inhibited the increase in activity level induced by MK-801.</p>
<p>It is known that NMDA receptors are involved in pain associated with peripheral tissues or nerve injuries [<xref ref-type="bibr" rid="B62">71</xref>–<xref ref-type="bibr" rid="B47">73</xref>]. It has already been reported that administration of MK-801 to mice causes an antinociceptive effect in the hot plate test [<xref ref-type="bibr" rid="B49">74</xref>]. The present study also showed that MK-801 has an analgesic effect in acute pain as previously reported. <italic>α</italic>-Pinene did not affect the MK-801-induced analgesic effect. Since the tail flick test and the acetic acid writhing test were not carried out and although details of the influence of <italic>α</italic>-pinene are unknown, <italic>α</italic>-pinene may not affect the peripheral sensory nervous system.</p>
<p>Several basic and clinical studies have shown that the glutamatergic system is widely involved in the pathophysiology of depression [<xref ref-type="bibr" rid="B60">75</xref>, <xref ref-type="bibr" rid="B51">76</xref>]. Therefore, administration of the NMDA receptor antagonist MK-801 exerts an antidepressant effect in an animal model of depression [<xref ref-type="bibr" rid="B44">77</xref>, <xref ref-type="bibr" rid="B68">78</xref>]. However, in this study, MK-801 administered mice showed no antidepressive behaviour. In this study, we did not use a mouse model of depression under chronic stress as was used in previous reports [<xref ref-type="bibr" rid="B44">77</xref>, <xref ref-type="bibr" rid="B68">78</xref>]. The difference in results is presumed to be due to the mouse model used. At least our study result showed that <italic>α</italic>-pinene may not exert antidepressant effects against sudden stress. In fact, in order to investigate the antidepressant effect of <italic>α</italic>-pinene, studies using mouse models of depression are necessary.</p>
<p>It has been reported that inhalation of <italic>α</italic>-pinene causes anxiolytic effects on mice during the elevated plus maze test [<xref ref-type="bibr" rid="B69">25</xref>] and antidepressant effects on rats in the forced swim test [<xref ref-type="bibr" rid="B37">79</xref>]. However, these results are from daily inhalation. In this experiment, we did not conduct some behavioural experiments using the group that inhaled only <italic>α</italic>-pinene for 30 minutes. Considering previous studies, it is speculated that <italic>α</italic>-pinene inhalation for only 30 minutes does not affect the normal behaviour of mice, but further studies are needed to clarify these observations.</p>
<p>
<italic>α</italic>-Pinene promotes the function of the GABA-A receptor and increases the postsynaptic GABA-dependent chloride flow in GABA-A receptors [<xref ref-type="bibr" rid="B2">80</xref>]. Furthermore, it has been reported that in mice, after oral ingestion, <italic>α</italic>-pinene binds to the benzodiazepine site of the GABA receptor and becomes a useful hypnotic agent [<xref ref-type="bibr" rid="B83">81</xref>]. As reported above, it is presumed that <italic>α</italic>-pinene acts on the brain through stimulation of the GABA receptor [<xref ref-type="bibr" rid="B35">82</xref>]. Benzodiazepines such as diazepam also exert sedative and anxiolytic effects via GABA receptors [<xref ref-type="bibr" rid="B9">83</xref>]. Conversely, monoterpenes such as <italic>α</italic>-pinene, citronellal, citronellol, and myrcene are reported NMDA receptors antagonists [<xref ref-type="bibr" rid="B28">84</xref>]. That is, <italic>α</italic>-pinene is considered to exert physiological effects such as anxiolytic and antioxidant effects through these mechanisms.</p>
<p>Importantly, it is not clear how odour molecules act on nerves through inhalation. One likely hypothesis is that the volatile compound <italic>α</italic>-pinene acts pharmacologically by entering the bloodstream through the mucosa of the nose or lung. The skin permeability of a drug has a high correlation with the lipid solubility or lipophilicity of the drug [<xref ref-type="bibr" rid="B70">85</xref>]. Drugs with molecular weights up to 100 kDa are easily absorbed from the nasal mucosa [<xref ref-type="bibr" rid="B24">86</xref>]. Since <italic>α</italic>-pinene has a low molecular weight and high lipophilicity [<xref ref-type="bibr" rid="B22">15</xref>, <xref ref-type="bibr" rid="B23">16</xref>], it is considered that it is easily absorbed from the nasal mucosa. For the same reasons, it is also expected to have good permeability in brain tissue. In mice, inhaled <italic>α</italic>-pinene has been shown to reach the brain [<xref ref-type="bibr" rid="B69">25</xref>]. From these reports, it is reasonable to hypothesise that inhaled <italic>α</italic>-pinene acts on the nerves and alleviates MK-801-induced neural activity abnormality. However, to our knowledge, there are currently no data on the pharmacokinetic interaction between <italic>α</italic>-pinene and MK-801. Further research is needed to clarify these issues.</p>
<p>This study is the first to analyse the effects of <italic>α</italic>-pinene inhalation on MK-801-induced behavioural abnormalities in mice through a series of behavioural tests. Our findings show that the odour of <italic>α</italic>-pinene-containing foodstuffs and essential oils has the effect of alleviating behavioural abnormalities associated with schizophrenia and at the same time presents the scientific basis for the physiological action of odours.</p>
</sec>
<sec id="sec5">
<title>5. Conclusions</title>
<p>In conclusion, inhalation of <italic>α</italic>-pinene reduces MK-801-induced psychiatric-like behavioural abnormalities in mice. Our results suggest that inhalation of essential oils containing <italic>α</italic>-pinene acts on nerves and suppresses abnormal activity increase of nerve cells. Thus, <italic>α</italic>-pinene can be a useful natural substance for the treatment and prevention of neuropsychiatric disorders.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank the Kawasaki Medical School Central Research Institute for providing instruments to support this study. The authors would also like to thank Editage (<ext-link ext-link-type="uri" xlink:href="http://www.editage.jp">www.editage.jp</ext-link>) for English language editing. This work is supported by the Towa Foundation for Food Science &amp; Research and the Kobayashi Magobe Memorial Medical Foundation.</p>
</ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>NMDA:</term>
<def>
<p>N-methyl-D-aspartate</p>
</def>
</def-item>
<def-item>
<term>ANOVA:</term>
<def>
<p>Analysis of variance.</p>
</def>
</def-item>
</def-list>
</glossary>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>All relevant data are within the article.</p>
</sec>
<sec sec-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare that they have no conflicts of interest.</p>
</sec>
<sec>
<title>Authors' Contributions</title>
<p>All authors had full access to all study data and take full responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Hiroshi Ueno, Atsumi Shimada, and Motoi Okamoto. Data acquisition: Hiroshi Ueno and Shunsuke Suemitsu. Data analysis and interpretation: Hiroshi Ueno, Atsumi Shimada, and Shunsuke Suemitsu. Drafting of the manuscript: Hiroshi Ueno, Atsumi Shimada, and Motoi Okamoto. Critical revision of the manuscript for important intellectual content: Atsumi Shimada, Shinji Murakami, Naoya Kitamura, Kenta Wani, Yosuke Matsumoto, Motoi Okamoto, and Takeshi Ishihara. Statistical analyses: Hiroshi Ueno and Shunsuke Suemitsu. Study supervision: Motoi Okamoto and Takeshi Ishihara.</p>
</sec>
<ref-list>
<ref id="B58">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pantelis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stuart</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>T. R.</given-names>
</name>
</person-group>
<article-title>Spatial Working Memory Deficits in Schizophrenia: Relationship With Tardive Dyskinesia and Negative Symptoms</article-title>
<source/>
<italic toggle="yes">The American Journal of Psychiatry</italic>
<year>2001</year>
<volume>158</volume>
<issue>8</issue>
<fpage>1276</fpage>
<lpage>1285</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.158.8.1276</pub-id>
<pub-id pub-id-type="pmid">11481163</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bora</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yucel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pantelis</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study</article-title>
<source/>
<italic toggle="yes">The British Journal of Psychiatry</italic>
<year>2009</year>
<volume>195</volume>
<issue>6</issue>
<fpage>475</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.bp.108.055731</pub-id>
<pub-id pub-id-type="other">2-s2.0-72149103832</pub-id>
<pub-id pub-id-type="pmid">19949193</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keefe</surname>
<given-names>R. S. E.</given-names>
</name>
<name>
<surname>Bilder</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>S. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial</article-title>
<source/>
<italic toggle="yes">Archives of General Psychiatry</italic>
<year>2007</year>
<volume>64</volume>
<issue>6</issue>
<fpage>633</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.64.6.633</pub-id>
<pub-id pub-id-type="other">2-s2.0-34247643916</pub-id>
<pub-id pub-id-type="pmid">17548746</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Ganocy</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Gajwani</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Calabrese</surname>
<given-names>J. R.</given-names>
</name>
</person-group>
<article-title>Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychopharmacology</italic>
<year>2008</year>
<volume>28</volume>
<issue>2</issue>
<fpage>203</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="doi">10.1097/jcp.0b013e318166c4d5</pub-id>
<pub-id pub-id-type="other">2-s2.0-40949136198</pub-id>
<pub-id pub-id-type="pmid">18344731</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nasrallah</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Keshavan</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Benes</surname>
<given-names>F. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proceedings and data from the Schizophrenia Summit: A critical appraisal to improve the management of schizophrenia</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychiatry</italic>
<year>2009</year>
<volume>70</volume>
<issue>1</issue>
<fpage>4</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="other">2-s2.0-63449119324</pub-id>
<pub-id pub-id-type="doi">10.4088/JCP.8157su1c.01</pub-id>
<pub-id pub-id-type="pmid">19292973</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakurai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bies</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Stroup</surname>
<given-names>S. T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data</article-title>
<source/>
<italic toggle="yes">Schizophrenia Bulletin</italic>
<year>2013</year>
<volume>39</volume>
<issue>3</issue>
<fpage>564</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbr189</pub-id>
<pub-id pub-id-type="pmid">22290266</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>X. N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z. J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Tzeng</surname>
<given-names>C. M.</given-names>
</name>
</person-group>
<article-title>Aromatherapy and the central nerve system (CNS): therapeutic mechanism and its associated genes</article-title>
<source/>
<italic toggle="yes">Current Drug Targets</italic>
<year>2013</year>
<volume>14</volume>
<issue>8</issue>
<fpage>872</fpage>
<lpage>879</lpage>
<pub-id pub-id-type="doi">10.2174/1389450111314080007</pub-id>
<pub-id pub-id-type="other">2-s2.0-84881342532</pub-id>
<pub-id pub-id-type="pmid">23531112</pub-id>
</element-citation>
</ref>
<ref id="B85">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessing the Metabolic Effects of Aromatherapy in Human Volunteers</article-title>
<source/>
<italic toggle="yes">Evidence-Based Complementary and Alternative Medicine</italic>
<year>2013</year>
<volume>2013</volume>
<fpage>9</fpage>
<pub-id pub-id-type="publisher-id">356381</pub-id>
<pub-id pub-id-type="doi">10.1155/2013/356381</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lis-Balchin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Essential oils and 'aromatherapy': their modern role in healing</article-title>
<source/>
<italic toggle="yes">Journal of the Royal Society of Health</italic>
<year>1997</year>
<volume>117</volume>
<issue>5</issue>
<fpage>324</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1177/146642409711700511</pub-id>
<pub-id pub-id-type="pmid">9519666</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Sousa</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>De Almeida Soares Hocayen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>L. N.</given-names>
</name>
<name>
<surname>Andreatini</surname>
<given-names>R. A.</given-names>
</name>
</person-group>
<article-title>A systematic review of the anxiolytic-like effects of essential oils in animal models</article-title>
<source/>
<italic toggle="yes">Molecules</italic>
<year>2015</year>
<volume>20</volume>
<issue>10</issue>
<fpage>18620</fpage>
<lpage>18660</lpage>
<pub-id pub-id-type="doi">10.3390/molecules201018620</pub-id>
<pub-id pub-id-type="other">2-s2.0-84947778216</pub-id>
<pub-id pub-id-type="pmid">26473822</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>11</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Simonsen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>W. C.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">The Triterpenes and Their Derivative S Hydroxy Acids, Hydroxy Lactones, Hydroxyaldehydo a Hardcover</italic>
<year>1957</year>
<edition>2nd</edition>
<publisher-name>Cambridge</publisher-name>
</element-citation>
</ref>
<ref id="B61">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira Limberger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mendes Aleixo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fett-Neto</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>T. Henriques</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Bioconversion of (+)- and (-)-alpha-pinene to (+)- and (-)-verbenone by plant cell cultures of Psychotria brachyceras and Rauvolfia sellowii</article-title>
<source/>
<italic toggle="yes">Electronic Journal of Biotechnology</italic>
<year>2007</year>
<volume>10</volume>
<issue>4</issue>
<fpage>0</fpage>
<lpage>0</lpage>
<pub-id pub-id-type="doi">10.2225/vol10-issue4-fulltext-8</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Da Silva</surname>
<given-names>A. C. R.</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>De Azevedo</surname>
<given-names>M. M. B.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>D. C. M.</given-names>
</name>
<name>
<surname>Alviano</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Alviano</surname>
<given-names>D. S.</given-names>
</name>
</person-group>
<article-title>Biological activities of <italic>α</italic>-pinene and <italic>β</italic>-pinene enantiomers</article-title>
<source/>
<italic toggle="yes">Molecules</italic>
<year>2012</year>
<volume>17</volume>
<issue>6</issue>
<fpage>6305</fpage>
<lpage>6316</lpage>
<pub-id pub-id-type="other">2-s2.0-84862975922</pub-id>
<pub-id pub-id-type="doi">10.3390/molecules17066317</pub-id>
<pub-id pub-id-type="pmid">22634841</pub-id>
</element-citation>
</ref>
<ref id="B76">
<label>14</label>
<element-citation publication-type="other">
<article-title>U.S. Food and Drug Administration</article-title>
<comment>2018</comment>
</element-citation>
</ref>
<ref id="B22">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gullstrand</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wigaeus-Hjelm</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Liquid/air partition coefficients of four terpenes</article-title>
<source/>
<italic toggle="yes">British Journal of Industrial Medicine</italic>
<year>1990</year>
<volume>47</volume>
<issue>1</issue>
<fpage>62</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="other">2-s2.0-0025060384</pub-id>
<pub-id pub-id-type="pmid">2310709</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falk</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Hagberg</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Lof</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Wigaeus-Hjelm</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z. P.</given-names>
</name>
</person-group>
<article-title>Uptake, distribution and elimination of alpha-pinene in man after exposure by inhalation.</article-title>
<source/>
<italic toggle="yes">Scandinavian Journal of Work, Environment &amp; Health</italic>
<year>1990</year>
<volume>16</volume>
<issue>5</issue>
<fpage>372</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="doi">10.5271/sjweh.1771</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mercier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Prost</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Prost</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The essential oil of turpentine and its major volatile fraction (<italic>α</italic>- and <italic>β</italic>-pinenes): A review</article-title>
<source/>
<italic toggle="yes">International Journal of Occupational Medicine and Environmental Health</italic>
<year>2009</year>
<volume>22</volume>
<issue>4</issue>
<fpage>331</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="other">2-s2.0-77749267767</pub-id>
<pub-id pub-id-type="doi">10.2478/v10001-009-0032-5</pub-id>
<pub-id pub-id-type="pmid">20197260</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Padilla</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ocete</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galvez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiménez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zarzuelo</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Anti-Inflammatory Activity of the Essential Oil of <italic>Bupleurum fruticescens</italic></article-title>
<source/>
<italic toggle="yes">Planta Medica</italic>
<year>1993</year>
<volume>59</volume>
<issue>06</issue>
<fpage>533</fpage>
<lpage>536</lpage>
<pub-id pub-id-type="doi">10.1055/s-2006-959755</pub-id>
<pub-id pub-id-type="pmid">8302953</pub-id>
</element-citation>
</ref>
<ref id="B86">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>F. D.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>G. G.</given-names>
</name>
<name>
<surname>Bian</surname>
<given-names>R. L.</given-names>
</name>
</person-group>
<article-title>Effect of alpha-pinene on nuclear translocation of NF-kappa B in THP-1 cells</article-title>
<source/>
<italic toggle="yes">Acta Pharmacologica Sinica</italic>
<year>2004</year>
<volume>25</volume>
<issue>4</issue>
<fpage>480</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="pmid">15066217</pub-id>
</element-citation>
</ref>
<ref id="B1">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Husain</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mujeeb</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A review on therapeutic potential of <italic>Nigella sativa</italic>: a miracle herb</article-title>
<source/>
<italic toggle="yes">Asian Pacific Journal of Tropical Biomedicine</italic>
<year>2013</year>
<volume>3</volume>
<issue>5</issue>
<fpage>337</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="doi">10.1016/S2221-1691(13)60075-1</pub-id>
<pub-id pub-id-type="other">2-s2.0-84875398742</pub-id>
<pub-id pub-id-type="pmid">23646296</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Consroe</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Antiepileptic potential of cannabidiol analogs</article-title>
<source/>
<italic toggle="yes">The Journal of Clinical Pharmacology</italic>
<year>1981</year>
<volume>21</volume>
<issue>S1</issue>
<fpage>428S</fpage>
<lpage>436S</lpage>
<pub-id pub-id-type="doi">10.1002/j.1552-4604.1981.tb02623.x</pub-id>
<pub-id pub-id-type="pmid">7298873</pub-id>
</element-citation>
</ref>
<ref id="B74">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>H. P.</given-names>
</name>
<name>
<surname>Batish</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kohli</surname>
<given-names>R. K.</given-names>
</name>
</person-group>
<article-title>
<italic>α</italic>-Pinene inhibits growth and induces oxidative stress in roots</article-title>
<source/>
<italic toggle="yes">Annals of Botany</italic>
<year>2006</year>
<volume>98</volume>
<issue>6</issue>
<fpage>1261</fpage>
<lpage>1269</lpage>
<pub-id pub-id-type="other">2-s2.0-33845252482</pub-id>
<pub-id pub-id-type="doi">10.1093/aob/mcl213</pub-id>
<pub-id pub-id-type="pmid">17028297</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eftekhar</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yousefzadi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borhani</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Antibacterial activity of the essential oil from Ferula gummosa seed</article-title>
<source/>
<italic toggle="yes">Fitoterapia</italic>
<year>2004</year>
<volume>75</volume>
<issue>7-8</issue>
<fpage>758</fpage>
<lpage>759</lpage>
<pub-id pub-id-type="doi">10.1016/j.fitote.2004.09.004</pub-id>
<pub-id pub-id-type="pmid">15567258</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Him</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ozbek</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Turel</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Oner</surname>
<given-names>A. C.</given-names>
</name>
</person-group>
<article-title>Antinociceptive activity of alpha-pinene and fenchone</article-title>
<source/>
<italic toggle="yes">Pharmacologyonline</italic>
<year>2008</year>
<volume>3</volume>
<fpage>363</fpage>
<lpage>369</lpage>
<pub-id pub-id-type="other">2-s2.0-58049088472</pub-id>
</element-citation>
</ref>
<ref id="B69">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Satou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kasuya</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Koike</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Daily Inhalation of <italic>α</italic>-Pinene in Mice: Effects on Behavior and Organ Accumulation</article-title>
<source/>
<italic toggle="yes">Phytotherapy Research</italic>
<year>2014</year>
<volume>28</volume>
<issue>9</issue>
<fpage>1284</fpage>
<lpage>1287</lpage>
<pub-id pub-id-type="doi">10.1002/ptr.5105</pub-id>
<pub-id pub-id-type="pmid">25340185</pub-id>
</element-citation>
</ref>
<ref id="B82">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamaoka</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Effects of Plant-derived Odors on Sleep-Wakefulness and Circadian Rhythmicity in Rats</article-title>
<source/>
<italic toggle="yes">Chemical Senses</italic>
<year>2005</year>
<volume>30</volume>
<issue>Supplement 1</issue>
<fpage>i264</fpage>
<lpage>i265</lpage>
<pub-id pub-id-type="doi">10.1093/chemse/bjh216</pub-id>
<pub-id pub-id-type="pmid">15738148</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kumakiri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Komatsu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Adenosine A1 Receptor Agonists Block the Neuropathological Changes in Rat Retrosplenial Cortex after Administration of the NMDA Receptor Antagonist Dizocilpine</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2004</year>
<volume>29</volume>
<issue>3</issue>
<fpage>544</fpage>
<lpage>550</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300351</pub-id>
<pub-id pub-id-type="pmid">14603270</pub-id>
</element-citation>
</ref>
<ref id="B81">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Stradtman</surname>
<given-names>G. G.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Dizocilpine (MK-801) induces distinct changes of N-methyl-d-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex</article-title>
<source/>
<italic toggle="yes">The International Journal of Neuropsychopharmacology</italic>
<year>2009</year>
<volume>12</volume>
<issue>10</issue>
<fpage>1395</fpage>
<lpage>1408</lpage>
<pub-id pub-id-type="doi">10.1017/S146114570900042X</pub-id>
<pub-id pub-id-type="pmid">19435549</pub-id>
</element-citation>
</ref>
<ref id="B75">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svoboda</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stankova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Entlerova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stuchlik</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Acute administration of MK-801 in an animal model of psychosis in rats interferes with cognitively demanding forms of behavioral flexibility on a rotating arena</article-title>
<source/>
<italic toggle="yes">Frontiers in Behavioral Neuroscience</italic>
<year>2015</year>
<volume>9</volume>
<pub-id pub-id-type="other">2-s2.0-84939800311</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murueta-Goyena</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Odrioizola</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Gargiulo</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Sánchez</surname>
<given-names>J. V. L.</given-names>
</name>
</person-group>
<article-title>Neuropathological background of mk-801 for inducing murine model of schizophrenia</article-title>
<source/>
<italic toggle="yes">Psychiatry and Neuroscience Update</italic>
<year>2017</year>
<volume>2</volume>
<fpage>337</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="other">2-s2.0-85033343381</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Behrens</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Dao</surname>
<given-names>D. N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase</article-title>
<source/>
<italic toggle="yes">Science</italic>
<year>2007</year>
<volume>318</volume>
<issue>5856</issue>
<fpage>1645</fpage>
<lpage>1647</lpage>
<pub-id pub-id-type="other">2-s2.0-36848999339</pub-id>
<pub-id pub-id-type="doi">10.1126/science.1148045</pub-id>
<pub-id pub-id-type="pmid">18063801</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braun</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Genius</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grunze</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Möller</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rujescu</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism</article-title>
<source/>
<italic toggle="yes">Schizophrenia Research</italic>
<year>2007</year>
<volume>97</volume>
<issue>1-3</issue>
<fpage>254</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2007.05.005</pub-id>
<pub-id pub-id-type="pmid">17601703</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilmour</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dix</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fellini</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NMDA receptors, cognition and schizophrenia—testing the validity of the NMDA receptor hypofunction hypothesis</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2012</year>
<volume>62</volume>
<issue>3</issue>
<fpage>1401</fpage>
<lpage>1412</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.03.015</pub-id>
<pub-id pub-id-type="other">2-s2.0-80054906982</pub-id>
<pub-id pub-id-type="pmid">21420987</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jadi</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Behrens</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Sejnowski</surname>
<given-names>T. J.</given-names>
</name>
</person-group>
<article-title>Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2016</year>
<volume>79</volume>
<issue>9</issue>
<fpage>716</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2015.07.005</pub-id>
<pub-id pub-id-type="pmid">26281716</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dauvermann</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research</article-title>
<source/>
<italic toggle="yes">British Journal of Pharmacology</italic>
<year>2017</year>
<volume>174</volume>
<issue>19</issue>
<fpage>3136</fpage>
<lpage>3160</lpage>
<pub-id pub-id-type="doi">10.1111/bph.13919</pub-id>
<pub-id pub-id-type="pmid">28626937</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javitt</surname>
<given-names>D. C.</given-names>
</name>
</person-group>
<article-title>Glutamate as a therapeutic target in psychiatric disorders</article-title>
<source/>
<italic toggle="yes">Molecular Psychiatry</italic>
<year>2004</year>
<volume>9</volume>
<issue>11</issue>
<fpage>984</fpage>
<lpage>997</lpage>
<pub-id pub-id-type="other">2-s2.0-8744278883</pub-id>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001551</pub-id>
<pub-id pub-id-type="pmid">15278097</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Glutamate Hypothesis of Schizophrenia and Approach for Possible Therapeutic Drugs</article-title>
<source/>
<italic toggle="yes">Current Medicinal Chemistry-Central Nervous System Agents</italic>
<year>2004</year>
<volume>4</volume>
<issue>2</issue>
<fpage>147</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.2174/1568015043357011</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coyle</surname>
<given-names>J. T.</given-names>
</name>
</person-group>
<article-title>Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms</article-title>
<source/>
<italic toggle="yes">Neurotoxicity Research</italic>
<year>2006</year>
<volume>10</volume>
<issue>3-4</issue>
<fpage>221</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1007/BF03033359</pub-id>
<pub-id pub-id-type="pmid">17197372</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conn</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Tamminga</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schoepp</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>Lindsley</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Schizophrenia: Moving Beyond Monoamine Antagonists</article-title>
<source/>
<italic toggle="yes">Molecular Interventions</italic>
<year>2008</year>
<volume>8</volume>
<issue>2</issue>
<fpage>99</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1124/mi.8.2.7</pub-id>
<pub-id pub-id-type="pmid">18403654</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisman</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>R. W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia</article-title>
<source/>
<italic toggle="yes">Trends in Neurosciences</italic>
<year>2008</year>
<volume>31</volume>
<issue>5</issue>
<fpage>234</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2008.02.005</pub-id>
<pub-id pub-id-type="pmid">18395805</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeon</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maslinic acid ameliorates NMDA receptor blockade-induced schizophrenia-like behaviors in mice</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2017</year>
<volume>126</volume>
<fpage>168</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.09.014</pub-id>
<pub-id pub-id-type="pmid">28899728</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enomoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ishibashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tokuda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ishiyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Toma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats</article-title>
<source/>
<italic toggle="yes">Behavioural Brain Research</italic>
<year>2008</year>
<volume>186</volume>
<issue>2</issue>
<fpage>197</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2007.08.012</pub-id>
<pub-id pub-id-type="pmid">17881065</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bubser</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bridges</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Dencker</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Selective Activation of M 4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents</article-title>
<source/>
<italic toggle="yes">ACS Chemical Neuroscience</italic>
<year>2014</year>
<volume>5</volume>
<issue>10</issue>
<fpage>920</fpage>
<lpage>942</lpage>
<pub-id pub-id-type="doi">10.1021/cn500128b</pub-id>
<pub-id pub-id-type="pmid">25137629</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>H. K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oleanolic acid attenuates MK-801-induced schizophrenia-like behaviors in mice</article-title>
<source/>
<italic toggle="yes">Neuropharmacology</italic>
<year>2014</year>
<volume>86</volume>
<fpage>49</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.06.025</pub-id>
<pub-id pub-id-type="pmid">24997455</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Neill</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Hicks</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Parameswaran</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cardwell</surname>
<given-names>G. P.</given-names>
</name>
<name>
<surname>O'Neill</surname>
<given-names>M. J.</given-names>
</name>
</person-group>
<article-title>Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine</article-title>
<source/>
<italic toggle="yes">The Journal of Pharmacology and Experimental Therapeutics</italic>
<year>1998</year>
<volume>287</volume>
<issue>3</issue>
<fpage>839</fpage>
<lpage>846</lpage>
<pub-id pub-id-type="other">2-s2.0-0032239446</pub-id>
<pub-id pub-id-type="pmid">9864262</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>van den Buuse</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Scarr</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hannan</surname>
<given-names>A. J.</given-names>
</name>
</person-group>
<article-title>Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation</article-title>
<source/>
<italic toggle="yes">The International Journal of Neuropsychopharmacology</italic>
<year>2009</year>
<volume>12</volume>
<issue>01</issue>
<fpage>45</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145708009085</pub-id>
<pub-id pub-id-type="pmid">18593507</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bygrave</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Masiulis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801</article-title>
<source/>
<italic toggle="yes">Translational Psychiatry</italic>
<year>2016</year>
<volume>6</volume>
<issue>4</issue>
<fpage>e778</fpage>
<lpage>e778</lpage>
<pub-id pub-id-type="doi">10.1038/tp.2016.44</pub-id>
<pub-id pub-id-type="pmid">27070406</pub-id>
</element-citation>
</ref>
<ref id="B77">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ueno</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suemitsu</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-depressive-like effect of 2-phenylethanol inhalation in mice</article-title>
<source/>
<italic toggle="yes">Biomedicine &amp; Pharmacotherapy</italic>
<year>2019</year>
<volume>111</volume>
<fpage>1499</fpage>
<lpage>1506</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2018.10.073</pub-id>
<pub-id pub-id-type="pmid">30415864</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koshimizu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matozaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Miyakawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Comprehensive Behavioral Analysis of Cluster of Differentiation 47 Knockout Mice</article-title>
<source/>
<italic toggle="yes">PLoS ONE</italic>
<year>2014</year>
<volume>9</volume>
<issue>2</issue>
<pub-id pub-id-type="publisher-id">e89584</pub-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0089584</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rompala</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Zsiros</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kolata</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Contribution of NMDA Receptor Hypofunction in Prefrontal and Cortical Excitatory Neurons to Schizophrenia-Like Phenotypes</article-title>
<source/>
<italic toggle="yes">PLoS ONE</italic>
<year>2013</year>
<volume>8</volume>
<issue>4</issue>
<pub-id pub-id-type="publisher-id">e61278</pub-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0061278</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuda</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Shoji</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Miyakawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Aiba</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Comprehensive behavioral phenotyping of a new Semaphorin 3 F mutant mouse</article-title>
<source/>
<italic toggle="yes">Molecular Brain</italic>
<year>2016</year>
<volume>9</volume>
<issue>1, article no. 15</issue>
<pub-id pub-id-type="other">2-s2.0-84959473619</pub-id>
<pub-id pub-id-type="doi">10.1186/s13041-016-0196-4</pub-id>
<pub-id pub-id-type="pmid">26856818</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>52</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Bansal</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Deshmukh</surname>
<given-names>R.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">Animal Models of Neurological Disorders. Principle and Working Procedure for Animal Models of Neurological Disorders</italic>
<year>2017</year>
<publisher-name>Springer</publisher-name>
<pub-id pub-id-type="other">2-s2.0-85045868463</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okonogi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ikegaya</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Characterization of peripheral activity states and cortical local field potentials of mice in an elevated plus maze test</article-title>
<source/>
<italic toggle="yes">Frontiers in Behavioral Neuroscience</italic>
<year>2018</year>
<volume>12</volume>
<pub-id pub-id-type="other">2-s2.0-85046701602</pub-id>
</element-citation>
</ref>
<ref id="B80">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Abner</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Ashkenazy-Frolinger</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hartz</surname>
<given-names>A. M. S.</given-names>
</name>
</person-group>
<article-title>A comprehensive behavioral test battery to assess learning and memory in 129S6/Tg2576 mice</article-title>
<source/>
<italic toggle="yes">PLoS ONE</italic>
<year>2016</year>
<volume>11</volume>
<issue>1</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0147733</pub-id>
<pub-id pub-id-type="publisher-id">e0147733</pub-id>
<pub-id pub-id-type="other">2-s2.0-84958794285</pub-id>
</element-citation>
</ref>
<ref id="B78">
<label>55</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Vogel</surname>
<given-names>H.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">Drug Discovery and Evaluation: Pharmacological Assays</italic>
<year>2007</year>
<publisher-name>Springer</publisher-name>
</element-citation>
</ref>
<ref id="B52">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakatani</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tamada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hatanaka</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism</article-title>
<source/>
<italic toggle="yes">Cell</italic>
<year>2009</year>
<volume>137</volume>
<issue>7</issue>
<fpage>1235</fpage>
<lpage>1246</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.04.024</pub-id>
<pub-id pub-id-type="other">2-s2.0-67549083336</pub-id>
<pub-id pub-id-type="pmid">19563756</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chartoff</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Heusner</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Palmiter</surname>
<given-names>R. D.</given-names>
</name>
</person-group>
<article-title>Dopamine is not Required for the Hyperlocomotor Response to NMDA Receptor Antagonists</article-title>
<source/>
<italic toggle="yes">Neuropsychopharmacology</italic>
<year>2005</year>
<volume>30</volume>
<issue>7</issue>
<fpage>1324</fpage>
<lpage>1333</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300678</pub-id>
<pub-id pub-id-type="pmid">15688082</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>58</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Belzung</surname>
<given-names>C.</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Crusio</surname>
<given-names>W. E.</given-names>
</name>
<name>
<surname>Gerlai</surname>
<given-names>R. T.</given-names>
</name>
</person-group>
<article-title>Measuring exploratory behavior</article-title>
<source/>
<italic toggle="yes">Handbook of molecular genetics techniques for brain and behavior research (techniques in the behavioral and neural sciences)</italic>
<year>1999</year>
<volume>13</volume>
<publisher-name>Elsevier</publisher-name>
<fpage>738</fpage>
<lpage>749</lpage>
<series>Techniques in the Behavioral and Neural Sciences</series>
<pub-id pub-id-type="doi">10.1016/S0921-0709(99)80057-1</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prut</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Belzung</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review</article-title>
<source/>
<italic toggle="yes">European Journal of Pharmacology</italic>
<year>2003</year>
<volume>463</volume>
<issue>1–3</issue>
<fpage>3</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-2999(03)01272-X</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037470154</pub-id>
<pub-id pub-id-type="pmid">12600700</pub-id>
</element-citation>
</ref>
<ref id="B84">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zamyad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abasnejad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Esmaeili-Mahani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mostafavi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Alpha-Pinene as the Main Component of Ducrosia anethifolia (Boiss) Essential Oil is Responsible for its Effect on Locomotor Activity in Rats</article-title>
<source/>
<italic toggle="yes">Avicenna Journal of Neuro Psych Physiology</italic>
<year>2016</year>
<volume>3</volume>
<issue>2</issue>
<pub-id pub-id-type="doi">10.17795/ajnpp-38787</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>R. J.</given-names>
</name>
</person-group>
<article-title>The NMDA antagonist MK-801 can impair attention to exteroceptive stimuli</article-title>
<source/>
<italic toggle="yes">Behavioural Brain Research</italic>
<year>1994</year>
<volume>62</volume>
<issue>2</issue>
<fpage>149</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1016/0166-4328(94)90022-1</pub-id>
<pub-id pub-id-type="pmid">7945965</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plaznik</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Palejko</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Nazar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jessa</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Effects of antagonists at the NMDA receptor complex in two models of anxiety</article-title>
<source/>
<italic toggle="yes">European Neuropsychopharmacology</italic>
<year>1994</year>
<volume>4</volume>
<issue>4</issue>
<fpage>503</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1016/0924-977X(94)90299-2</pub-id>
<pub-id pub-id-type="pmid">7894261</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>G. Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>J. H.</given-names>
</name>
</person-group>
<article-title>Amelioration of Scopolamine-Induced Learning and Memory Impairment by <italic>α</italic>-Pinene in C57BL/6 Mice</article-title>
<source/>
<italic toggle="yes">Evidence-Based Complementary and Alternative Medicine</italic>
<year>2017</year>
<volume>2017</volume>
<fpage>9</fpage>
<pub-id pub-id-type="publisher-id">4926815</pub-id>
<pub-id pub-id-type="doi">10.1155/2017/4926815</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>S. K.</given-names>
</name>
</person-group>
<article-title>MK-801 produces antianxiety effect in elevated plus-maze in mice</article-title>
<source/>
<italic toggle="yes">Drug Development Research</italic>
<year>1991</year>
<volume>22</volume>
<issue>3</issue>
<fpage>251</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="doi">10.1002/ddr.430220307</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertoglio</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Carobrez</surname>
<given-names>A. P.</given-names>
</name>
</person-group>
<article-title>Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats</article-title>
<source/>
<italic toggle="yes">Psychopharmacology</italic>
<year>2003</year>
<volume>170</volume>
<issue>4</issue>
<fpage>335</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-003-1558-z</pub-id>
<pub-id pub-id-type="pmid">13680083</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choy</surname>
<given-names>K. H. C.</given-names>
</name>
<name>
<surname>de Visser</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nichols</surname>
<given-names>N. R.</given-names>
</name>
<name>
<surname>van den Buuse</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Combined neonatal stress and young-adult glucocorticoid stimulation in rats reduce BDNF expression in hippocampus: effects on learning and memory</article-title>
<source/>
<italic toggle="yes">Hippocampus</italic>
<year>2008</year>
<volume>18</volume>
<issue>7</issue>
<fpage>655</fpage>
<lpage>667</lpage>
<pub-id pub-id-type="doi">10.1002/hipo.20425</pub-id>
<pub-id pub-id-type="other">2-s2.0-47749135849</pub-id>
<pub-id pub-id-type="pmid">18398848</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shipton</surname>
<given-names>O. A.</given-names>
</name>
<name>
<surname>El-Gaby</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Apergis-Schoute</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Left–right dissociation of hippocampal memory processes in mice</article-title>
<source/>
<italic toggle="yes">Proceedings of the National Acadamy of Sciences of the United States of America</italic>
<year>2014</year>
<volume>111</volume>
<issue>42</issue>
<fpage>15238</fpage>
<lpage>15243</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1405648111</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mihara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mihara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yarimizu</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacological Characterization of a Novel, Potent Adenosine A1 and A2A Receptor Dual Antagonist, 5-[5-Amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in Models of Parkinson's Disease and Cognition</article-title>
<source/>
<italic toggle="yes">The Journal of Pharmacology and Experimental Therapeutics</italic>
<year>2007</year>
<volume>323</volume>
<issue>2</issue>
<fpage>708</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.107.121962</pub-id>
<pub-id pub-id-type="pmid">17684118</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okuyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fukata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nishigawa</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Citrus flavonoid improves MK-801-induced locomotive hyperactivity: Possible relevance to schizophrenia</article-title>
<source/>
<italic toggle="yes">Journal of Functional Foods</italic>
<year>2013</year>
<volume>5</volume>
<issue>4</issue>
<fpage>2002</fpage>
<lpage>2006</lpage>
<pub-id pub-id-type="doi">10.1016/j.jff.2013.07.016</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasegawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawaminami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Effects of scallop shell extract on scopolamine-induced memory impairment and MK801-induced locomotor activity</article-title>
<source/>
<italic toggle="yes">Asian Pacific Journal of Tropical Medicine</italic>
<year>2016</year>
<volume>9</volume>
<issue>7</issue>
<fpage>662</fpage>
<lpage>667</lpage>
<pub-id pub-id-type="doi">10.1016/j.apjtm.2016.05.019</pub-id>
<pub-id pub-id-type="pmid">27393094</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrenko</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Yamakura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shimoji</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The Role of N-Methyl-d-Aspartate (NMDA) Receptors in Pain: A Review</article-title>
<source/>
<italic toggle="yes">Anesthesia &amp; Analgesia</italic>
<year>2003</year>
<fpage>1108</fpage>
<lpage>1116</lpage>
<pub-id pub-id-type="doi">10.1213/01.ANE.0000081061.12235.55</pub-id>
<pub-id pub-id-type="pmid">14500166</pub-id>
</element-citation>
</ref>
<ref id="B79">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willert</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Woolf</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Hobson</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>The Development and Maintenance of Human Visceral Pain Hypersensitivity Is Dependent on the N-Methyl-D-Aspartate Receptor</article-title>
<source/>
<italic toggle="yes">Gastroenterology</italic>
<year>2004</year>
<volume>126</volume>
<issue>3</issue>
<fpage>683</fpage>
<lpage>692</lpage>
<pub-id pub-id-type="other">2-s2.0-1542317629</pub-id>
<pub-id pub-id-type="doi">10.1053/j.gastro.2003.11.047</pub-id>
<pub-id pub-id-type="pmid">14988822</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McRoberts</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ennes</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Marvizón</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fanselow</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vissel</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Selective knockdown of NMDA receptors in primary afferent neurons decreases pain during phase 2 of the formalin test</article-title>
<source/>
<italic toggle="yes">Neuroscience</italic>
<year>2011</year>
<volume>172</volume>
<fpage>474</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.10.045</pub-id>
<pub-id pub-id-type="pmid">20974228</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meymandi</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Keyhanfar</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sepehri</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Heravi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yazdanpanah</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>The contribution of NMDA receptors in antinociceptive effect of pregabalin: Comparison of two models of pain assessment</article-title>
<source/>
<italic toggle="yes">Anesthesiology and Pain Medicine</italic>
<year>2017</year>
<volume>7</volume>
<issue>3</issue>
<pub-id pub-id-type="publisher-id">e14602</pub-id>
<pub-id pub-id-type="other">2-s2.0-85026443307</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paul</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Skolnick</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Glutamate and Depression</article-title>
<source/>
<italic toggle="yes">Annals of the New York Academy of Sciences</italic>
<year>2003</year>
<volume>1003</volume>
<issue>1</issue>
<fpage>250</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="doi">10.1196/annals.1300.016</pub-id>
<pub-id pub-id-type="pmid">14684451</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shirayama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ashby</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Correlation between plasma levels of glutamate, alanine and serine with severity of depression</article-title>
<source/>
<italic toggle="yes">Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</italic>
<year>2006</year>
<volume>30</volume>
<issue>6</issue>
<fpage>1155</fpage>
<lpage>1158</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.03.036</pub-id>
<pub-id pub-id-type="pmid">16707201</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantovani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pértile</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Calixto</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A. R. S.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>A. L. S.</given-names>
</name>
</person-group>
<article-title>Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway</article-title>
<source/>
<italic toggle="yes">Neuroscience Letters</italic>
<year>2003</year>
<volume>343</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1016/s0304-3940(03)00306-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037717094</pub-id>
<pub-id pub-id-type="pmid">12749983</pub-id>
</element-citation>
</ref>
<ref id="B68">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanacora</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zarate</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Manji</surname>
<given-names>H. K.</given-names>
</name>
</person-group>
<article-title>Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders</article-title>
<source/>
<italic toggle="yes">Nature Reviews Drug Discovery</italic>
<year>2008</year>
<volume>7</volume>
<issue>5</issue>
<fpage>426</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.1038/nrd2462</pub-id>
<pub-id pub-id-type="pmid">18425072</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhalation of Roman chamomile essential oil attenuates depressive-like behaviors in Wistar Kyoto rats</article-title>
<source/>
<italic toggle="yes">Science China Life Sciences</italic>
<year>2017</year>
<volume>60</volume>
<issue>6</issue>
<fpage>647</fpage>
<lpage>655</lpage>
<pub-id pub-id-type="doi">10.1007/s11427-016-9034-8</pub-id>
<pub-id pub-id-type="pmid">28527112</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoshima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hamamoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Potentiation of GABAA receptors expressed in Xenopus oocytes by perfume and phytoncid</article-title>
<source/>
<italic toggle="yes">Bioscience, Biotechnology, and Biochemistry</italic>
<year>1999</year>
<volume>63</volume>
<issue>4</issue>
<fpage>743</fpage>
<lpage>748</lpage>
<pub-id pub-id-type="doi">10.1271/bbb.63.743</pub-id>
</element-citation>
</ref>
<ref id="B83">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pae</surname>
<given-names>A. N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>α</italic>-pinene, a major constituent of pine tree oils, enhances non-rapid eye movement sleep in mice through GABAA-benzodiazepine receptors</article-title>
<source/>
<italic toggle="yes">Molecular Pharmacology</italic>
<year>2016</year>
<volume>90</volume>
<issue>5</issue>
<fpage>530</fpage>
<lpage>539</lpage>
<pub-id pub-id-type="other">2-s2.0-84992697260</pub-id>
<pub-id pub-id-type="doi">10.1124/mol.116.105080</pub-id>
<pub-id pub-id-type="pmid">27573669</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasture</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Chopde</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Deshmukh</surname>
<given-names>V. K.</given-names>
</name>
</person-group>
<article-title>Anticonvulsive activity of Albizzia lebbeck, Hibiscus rosa sinesis and Butea monosperma in experimental animals</article-title>
<source/>
<italic toggle="yes">Journal of Ethnopharmacology</italic>
<year>2000</year>
<volume>71</volume>
<issue>1-2</issue>
<fpage>65</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="other">2-s2.0-0033920732</pub-id>
<pub-id pub-id-type="doi">10.1016/S0378-8741(99)00192-0</pub-id>
<pub-id pub-id-type="pmid">10904147</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>83</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Brunton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lazo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>K.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">Goodman And Gilman's The Pharmacological Basis of Therapeutics</italic>
<year>2006</year>
<edition>11th</edition>
<publisher-name>McGraw-Hill Education / Medical</publisher-name>
</element-citation>
</ref>
<ref id="B28">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guimarães</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Quintans</surname>
<given-names>J. S. S.</given-names>
</name>
<name>
<surname>Quintans-Júnior</surname>
<given-names>L. J.</given-names>
</name>
</person-group>
<article-title>Monoterpenes with analgesic activity—a systematic review</article-title>
<source/>
<italic toggle="yes">Phytotherapy Research</italic>
<year>2013</year>
<volume>27</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1002/ptr.4686</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872093241</pub-id>
<pub-id pub-id-type="pmid">23296806</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheuplein</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Blank</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Brauner</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Macfarlane</surname>
<given-names>D. J.</given-names>
</name>
</person-group>
<article-title>Percutaneous Absorption of Steroids∗</article-title>
<source/>
<italic toggle="yes">Journal of Investigative Dermatology</italic>
<year>1969</year>
<volume>52</volume>
<issue>1</issue>
<fpage>63</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1038/jid.1969.9</pub-id>
<pub-id pub-id-type="pmid">5761930</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fisher</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Parr</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D. A.</given-names>
</name>
</person-group>
<article-title>The effect of molecular size on the nasal absorption of water‐soluble compounds in the albino rat</article-title>
<source/>
<italic toggle="yes">Journal of Pharmacy and Pharmacology</italic>
<year>1987</year>
<volume>39</volume>
<issue>5</issue>
<fpage>357</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="other">2-s2.0-0023222323</pub-id>
<pub-id pub-id-type="doi">10.1111/j.2042-7158.1987.tb03398.x</pub-id>
<pub-id pub-id-type="pmid">2441020</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="fig1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Effect of <italic>α</italic>-pinene on MK-801-induced hyperlocomotion in the locomotor activity test. Results of the locomotor activity test in the three groups. Spontaneous locomotor activity in each 10-min period (a). After 60 min, animals were injected with MK-801 or saline, and locomotor activity was assessed for 180 min. Total beam breaks for 60 min before injection of MK-801 or saline (b). Total beam breaks for 120 min after injection of MK-801 or saline (c). Data are presented as the mean ± SEM (a), or box plots (b, c). <italic>∗</italic>, significant difference among groups (p &lt; 0.05). The p values were calculated using two-way repeated measures analysis of variance in (a) and Student's t-test in ((b), (c)).</p>
</caption>
<graphic xlink:href="ECAM2019-2745453.001"></graphic>
</fig>
<fig id="fig2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Effect of <italic>α</italic>-pinene on MK-801-induced hyperlocomotion in the open field test. Graphs showing the distance travelled (a) and time spent in the central area (b) in each 5 min-period of the open field test. Graphs showing the total distance travelled (c) and total time spent in the central area (d) in the open field test. All data are presented as box plots. <italic>∗</italic>, significant difference among groups (p &lt; 0.05). The p-values were calculated using two-way repeated measures analysis of variance in (a, b) and one-way analysis of variance in ((c), (d)).</p>
</caption>
<graphic xlink:href="ECAM2019-2745453.002"></graphic>
</fig>
<fig id="fig3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Effect of <italic>α</italic>-pinene on MK-801-induced abnormal behaviour in the elevated plus maze test. Graphs showing the total distance travelled (a), the number of open arm entries (b), and the time spent in the open arms (c) in the elevated plus maze test. All data are presented as box plots. <italic>∗</italic>, significant difference among groups (p &lt; 0.05). The p-values were calculated using one-way analysis of variance in ((a)–(c)).</p>
</caption>
<graphic xlink:href="ECAM2019-2745453.003"></graphic>
</fig>
<fig id="fig4" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Effect of <italic>α</italic>-pinene on MK-801 induced cognitive deficits in the Y-maze test. Graphs showing the total distance travelled (a), total number of arm entries (b), and percentage of alterations (c). All data are presented as box plots. <italic>∗</italic>, significant difference among groups (p &lt; 0.05). The p-values were calculated using the one-way analysis of variance in ((a)–(c)).</p>
</caption>
<graphic xlink:href="ECAM2019-2745453.004"></graphic>
</fig>
<fig id="fig5" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>Effect of <italic>α</italic>-pinene on MK-801-induced antinociceptive effects in the hot plate test and grip strength test. (a) Latency to the first fore- or hind-paw response in the hot plate test. (b) Grip strength. All data are presented as box plots. <italic>∗</italic>, significant difference among groups (p &lt; 0.05). The p-values were calculated using one-way analysis of variance in ((a)–(c)).</p>
</caption>
<graphic xlink:href="ECAM2019-2745453.005"></graphic>
</fig>
<fig id="fig6" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<p>Effect of <italic>α</italic>-pinene on MK-801-induced antidepressant behaviour in the tail suspension test. Graphs showing the proportion of total time spent immobile (a) and the proportion of time spent immobile in each 1-min period (b) in the tail suspension test. All data are presented as box plots. <italic>∗</italic>, significant difference among groups (p &lt; 0.05). The p-values were calculated using one-way analysis of variance in (a) and two-way repeated measures analysis of variance in (b).</p>
</caption>
<graphic xlink:href="ECAM2019-2745453.006"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>